Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of April 4, 2022, the Board of Directors (the "Board") of Vir
Biotechnology, Inc. (the "Company") appointed Johanna Friedl-Naderer, age 54, to
serve as Executive Vice President and Chief Operating Officer of the Company. As
Chief Operating Officer, Ms. Friedl-Naderer is responsible for overseeing the
Company's business development, finance, product development/regulatory and
corporate affairs operations. Previously, Ms. Friedl-Naderer served as the
Company's Executive Vice President and Chief Business Officer, Global from March
2022 to April 2022. Prior to joining the Company, Ms. Friedl-Naderer held
various positions at Biogen Inc. ("Biogen") from February 2001 to January 2022,
most recently serving as President of Europe, Canada & Partner Markets at Biogen
and as a member of Biogen's Global Leadership Team, where she was fully
responsible for the regional P&L and working on global commercial aspects of the
business including strategy, planning and execution. During her more than
20-year tenure at Biogen, she held positions of increasing responsibility across
a wide range of functions, building and leading teams in advancing access to
medicines for the treatment of neurological conditions, including multiple
sclerosis, spinal muscular atrophy, amyotrophic lateral sclerosis and
Alzheimer's disease. Ms. Friedl-Naderer has also served on several boards of
directors, including the boards of directors of the European Federation of
Pharmaceutical Industries & Associations (EFPIA), the Swiss-American Chamber of
Commerce, Interpharma and the council of the International Federation of
Pharmaceutical Manufacturers and Associations (IFPMA).
There are no arrangements or understandings between Ms. Friedl-Naderer and any
other person pursuant to which she was selected as Chief Operating Officer of
the Company, and there is no family relationship between Ms. Friedl-Naderer and
any of the Company's directors or executive officers. Ms. Friedl-Naderer has no
direct or indirect interest in any transaction required to be disclosed pursuant
to Item 404(a) of Regulation S-K.
As of the filing of this Current Report on Form 8-K (this "Report"), the
Compensation Committee of the Board and the Board have not determined the
compensation of Ms. Friedl-Naderer in connection with her new appointment. The
Company will provide this information by filing an amendment to this Report
after the information is determined or becomes available.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
VIR BIOTECHNOLOGY, INC. 
